Z-YVAD-FMK NLT 98%

AA-Z-YVAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor with anti-inflammatory and anti-tumor activities. In Vitro: Z-YVAD-FMK (100 μM; 24 hours) significantly downregulated the growth inhibition induced by butyrate in Caco-2 cells^[1].
Z-YVAD-FMK (20 μM; pre 1 hour; 24 hours) attenuates the apoptotic induction of III-10 on both HepG2 and BEL-7402 cells, the apoptotic rate of -10 on HepG2 cells is reduced by Z-VAD-FMK from 19.88% to 8.34%, while that on BEL-7402 cells is reduced from 17.56% to 11.98%^[4].
Z-YVAD-FMK (1-10 μM; 24 hours) shows inhibitory effect in various cells against TNFr- or anti-CD95-induced cell death, exhibits IC₅₀ values of 0.0015 μM (Murine hepatocytes), 0.027 μM (Murine hepatocytes), 4.8 μM (HepG2), 5.8 μM (HepG2), 1.6 μM (Hela) and 1.1 μM (Jurkat), respectively^[5].
In Vivo: Z-VAD-FMK (intraperitoneal injection; 10mg/kg; pre- 30 minutes) significantly delayed preterm delivery at 18 hours, but after 36 hours treatment, non different exists between Z-VAD-FMK-pretreated and control groups^[3].